Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

A man suffering alopecia says he is being denied a groundbreaking new drug – despite it being approved. The daily pill, ...

Pfizer announced today a groundbreaking advancement in treating severe alopecia areata in the UAE for patients as young as 12 years old.This new once-daily oral capsule is an important milestone ...

Earlier this year, a new drug was recommended on the NHS in England and Wales for the first time for patients aged 12 and over with severe alopecia areata. Alopecia is caused by the immune system ...

Treatment with ritlecitinib sustained hair regrowth through week 48 in patients with alopecia areata (AA), and up to ... This study was funded by Pfizer. Piliang disclosed being a consultant ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as increasing research and development efforts in ...